PNC Financial Services Group
INM icon

PNC Financial Services Group’s InMed Pharmaceuticals INM Stock Holding History

PNC Financial Services Group’s Portfolio INM Stock Details INM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-4
Closed -$3K – 4521
2021
Q3 		$3K Hold
4
– – ﹤0.01% 4039
2021
Q2 		$6K Hold
4
– – ﹤0.01% 3833
2021
Q1 		$6K Hold
4
– – ﹤0.01% 3774
2020
Q4 		$6K Buy
+4
New +$6.5K ﹤0.01% 3678

Other funds holding INM

Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return
TWC
TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return
AWM
AllSquare Wealth Management Albany, New York $189M AUM 14.89% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
RFA
Reilly Financial Advisors La Mesa, California $1.35B AUM 22.65% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

PNC Financial Services Group's INM Position: Q4 2021 in Review

PNC Financial Services Group sold out of InMed Pharmaceuticals (INM) in Q4 2021, closing a stake of 4 shares — an estimated $3K sold.

PNC Financial Services Group first reported a position in INM in Q4 2020 and held it in 4 quarters. The position peaked at $6K in Q2 2021. 12 funds tracked by Wall St. Rank hold INM as of Q4 2021.

  • PNC Financial Services Group reported no remaining InMed Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
  • PNC Financial Services Group sold 4 InMed Pharmaceuticals shares in Q4 2021, an estimated $3K.
  • PNC Financial Services Group first reported a position in InMed Pharmaceuticals in Q4 2020 and held it in 4 quarters.
  • PNC Financial Services Group's InMed Pharmaceuticals position peaked at $6K in Q2 2021.
  • 12 funds tracked by Wall St. Rank held InMed Pharmaceuticals as of Q4 2021.

Based on PNC Financial Services Group's 13F filing for Q4 2021, filed 11 Feb 2022.